In the SURMOUNT program (SM), treatment with tirzepatide led to a significant and clinically meaningful reduction in body weight (BW) in overweight and obese subjects. In a post-hoc analysis, the effect of tirzepatide treatment on body weight in women was examined according to the stage of menopause.
Autoren
- Jens Dehn
Publikation
- InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
You May Also Like
- "Patients W.A.I.T Indicator"
Access to medicines – how does Switzerland compare across Europe?
- Adherence in severe or poorly controlled asthma
Digital monitoring with potential for greater treatment adherence
- Crohn's disease and depression
Significant psychological stress for CD patients
- Epilepsy
Cannabidiol for refractory epilepsy syndromes
- Stomach cancer and Helicobacter pylori
A question of income?
- Prurigo nodularis and AD
Effective itch relief through inhibition of the IL-31 signaling pathway
- Cutaneous Crohn's disease
Effective alternative to TNF inhibitors
- Palliative care symptom and needs assessment.